- Home
- RIGL vs LCLN Comparison
RIGL vs LCLN Comparison
Compare RIGL & LCLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | LCLN |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.9M | 821.7M |
| IPO Year | 2000 | 2026 |
Fundamental Metrics
Financial Performance| Metric | RIGL | LCLN |
|---|---|---|
| Price | $49.17 | $24.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $63.00 | $26.86 |
| AVG Volume (30 Days) | 194.5K | ★ 541.5K |
| Earning Date | 11-03-2026 | 11-15-2026 |
| Dividend Yield | N/A | ★ 1.15% |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | $3.89 | $28.21 |
| Revenue Next Year | $21.95 | $15.25 |
| P/E Ratio | $36.91 | ★ N/A |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $24.84 | $20.05 |
| 52 Week High | $52.24 | $27.55 |
Technical Indicators
Market Signals| Indicator | RIGL | LCLN |
|---|---|---|
| Relative Strength Index (RSI) | 59.28 | 53.57 |
| Support Level | $33.93 | $23.01 |
| Resistance Level | $49.50 | $25.60 |
| Average True Range (ATR) | 1.86 | 0.97 |
| MACD | -0.07 | 0.05 |
| Stochastic Oscillator | 74.01 | 82.61 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About LCLN Lincoln International Inc. Class A Common Stock
Lincoln International Inc is an independent investment banking advisory company focused on private capital markets. The company operates its business through its two operating segments: Investment Banking Advisory and Valuations and Opinions. The Investment Banking Advisory segment offers a range of services related to mergers and acquisitions, with key areas of focus including sell-side advisory, buy-side advisory, asset sales and divestitures, restructuring, primary and secondary capital raising, and merger-related engagements. The Valuations and Opinions segment provides valuation services to investment funds and financial institutions. The majority of revenue is derived from the Investment Banking Advisory segment. Geographically, the maximum revenue is derived from the Americas.